Endowed Chair Professor, Basic Medical Sciences
Professor, Radiation Oncology
Professor, Biomedical Engineering
Professor, Biomedical Engineering - GIDP
Dr. Frederic Zenhausern is Professor of Basic Medical Sciences and Radiation Oncology at the College of Medicine, Phoenix and founder director of the Center for Applied Nanobioscience and Medicine (ANBM) at the University of Arizona (UofA). Prior to joining the University of Arizona, Dr. Zenhausern was founder director of the Center for Applied Nanobioscience at the Arizona State University’s Biodesign Institute, and co-founder and R&D director of the first phase of the Center for Flexible Display and then Chief Technology Officer of the MacroTechnology Works. Zenhausern was also tenured Professor with both the Electrical Department and the School of Materials at the Ira A. Fulton School of Engineering.
Dr. Zenhausern is Director of the Laboratory for Research in Personalized Medicine at the HonorHealth Research Institute at Scottsdale Shea Campus. He is a Professor at the Translational Genomics Research Institute (TGen). Over a decade, Zenhausern held corporate research positions at IBM Research Division and Motorola Labs.
Dr. Zenhausern received his B.S. in biochemistry from the University of Geneva, his M.B.A. in finance from Rutgers University and his Doctorate Es Science in Applied Physics from the Department of Condensed Physics Matter at the University of Geneva. He has co-authored 70 scientific publications and over a dozen U.S. patents. Zenhausern founded several startups and currently sit on several corporate scientific boards. He is also a recipient of several prizes and an elected fellow of the National Academy of Inventors.
Dr. Zenhausern has broad experience in leading large international, multi-disciplinary research programs, academic and corporate ventures combined with two decades translating discoveries into product platforms in Life Sciences. Today, he serves in his capacity of senior academic leader in creating high quality intellectual assets, promoting teaching excellence, knowledge dissemination and sharing, while stimulating active engagement with diverse categories of scientific and clinical partners for high societal impact.
In the application for the Cancer Center Support Grant, his work in biomarkers discovery, assay integration and platform technology development provided the core activities supporting the entire team providing innovative solutions to the preparation of samples to their analysis using advanced molecular techniques. His experience in similar development of integrated biological systems and their functional characterization will provide the critical components for addressing the innovative design and biological validation studies necessary for prototyping high quality platforms.
Dr. Zenhausern has the expertise, leadership and motivation necessary to successfully carry out the proposed work while providing access to our center’s interdisciplinary infrastructure. He has a broad background in materials science, physics, engineering and genomics, with specific training and expertise in key research areas for this proposal. His scientific director roles at multiple academic, research and clinical institutions will serve the proposed program and allow mentoring and supervising the other team members for enabling translating our discoveries into practical platform technologies. His experience in leading platform technologies development in biological metrology, genomics, proteomics and physical sciences to translate biomarker panels into integrated tools for molecualr-based companion diagnostics tests will benefit the program and team.
Dr. Zenhausern has a broad research background in tumor and transplant immunology and hematopoietic stem and progenitor cell biology. His current research includes 1) studying the molecular mechanisms of myeloid differentiation and immune regulation, 2) identifying novel therapies to suppress graft-versus-host (GvHD) while promoting graft-versus-leukemia (GvL) effects using murine bone marrow transplant (BMT) models.